Sorveglianza della salute del pancreas dopo diagnosi del diabete (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: SAFE-D Trial Manager
- Numero di telefono: +442381205154
- Email: safed@soton.ac.uk
Luoghi di studio
-
-
-
Ashton-under-Lyne, Regno Unito, OL6 6HD
- Attivo, non reclutante
- Ashton Medical Group
-
Birmingham, Regno Unito, B14 4DU
- Reclutamento
- Yardley Wood Health Centre
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Bournemouth, Regno Unito, BH7 7DW
- Attivo, non reclutante
- Bournemouth Research Hub
-
Bromborough, Regno Unito, CH62 6EE
- Reclutamento
- Eastham Group Practice
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
London, Regno Unito, NW10 2PT
- Reclutamento
- Willesden Medical Centre
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
London, Regno Unito, SW1P 2PF
- Reclutamento
- South Westminster Centre
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
London, Regno Unito, W7 1DR
- Reclutamento
- The Cuckoo Lane Practice
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Manchester, Regno Unito, M14 6WP
- Attivo, non reclutante
- Bodey Medical Centre
-
Manchester, Regno Unito, M23 1JX
- Attivo, non reclutante
- Bowland Medical Practice
-
Manchester, Regno Unito, M23 2SY
- Attivo, non reclutante
- The Maples Medical Centre
-
Nottingham, Regno Unito, NG17 4JL
- Reclutamento
- King's Mill Hospital (Sherwood Forest) Research Van
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Portsmouth, Regno Unito, PO1 3HN
- Attivo, non reclutante
- Portsmouth Research Hub
-
Rossendale, Regno Unito, BB4 5SL
- Reclutamento
- Hazelvalley Family Practice
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Ruislip, Regno Unito, HA4 8NX
- Reclutamento
- Pembroke Centre (Hillingdon)
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Southampton, Regno Unito, SO30 3JB
- Reclutamento
- Moorgreen Hospital
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Southampton, Regno Unito, SO15 33UA
- Attivo, non reclutante
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter, Regno Unito, ST14 8JG
- Reclutamento
- Balance Street Health Centre
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Uxbridge, Regno Unito, UB8 1UW
- Reclutamento
- Civic Centre
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Walsall, Regno Unito, WS6 6EW
- Reclutamento
- Quinton Practice
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Weymouth, Regno Unito, DT4 0QE
- Attivo, non reclutante
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach, Cheshire, Regno Unito, CW11 1EQ
- Attivo, non reclutante
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone, Kent, Regno Unito, ME16 9QQ
- Reclutamento
- Maidstone and Tunbridge Wells NHS Trust
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester, Leicester Forest East, Regno Unito, LE3 3LW
- Reclutamento
- Forest Medical Group
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp, Leicestershire, Regno Unito, LE8 0LG
- Reclutamento
- South Leicestershire Medical Group
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent, Staffordshire, Regno Unito, DE14 3RH
- Reclutamento
- Peel Croft Surgery
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Kingswinford, Staffordshire, Regno Unito, DY6 8DN
- Reclutamento
- Kingswinford Medical Practice
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Leek, Staffordshire, Regno Unito, ST13 6QR
- Reclutamento
- Park Medical Centre
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Stratford-upon-Avon, Staffordshire, Regno Unito, CV37 6HJ
- Reclutamento
- Trinity Court Surgery
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
-
Surrey
-
Brockham, Surrey, Regno Unito, RH3 7NJ
- Reclutamento
- Brockwood Medical Practice
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Epsom, Surrey, Regno Unito, KT17 4BL
- Reclutamento
- Integrated Care Partnership/ The Old Cottage Hospital
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
Warlingham, Surrey, Regno Unito, CR6 9NW
- Reclutamento
- Warlingham Green Medical Practice
-
Contatto:
- Anson-Wisniewska
- Numero di telefono: 02380215154
- Email: safed@soton.ac.uk
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sensitivity of the Avantect test
Lasso di tempo: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
Lasso di tempo: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Stage shift
Lasso di tempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
Lasso di tempo: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
Lasso di tempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
Lasso di tempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
Lasso di tempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time-to-event outcomes
Lasso di tempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
Lasso di tempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
Lasso di tempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
Lasso di tempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Neoplasie per sede
- Neoplasie
- Malattie metaboliche
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Disturbi del metabolismo del glucosio
- Neoplasie delle ghiandole endocrine
- Malattie pancreatiche
- Malattie nutrizionali e metaboliche
- Diabete mellito, tipo 2
- Neoplasie pancreatiche
- Diabete mellito
- Cancro pancreatico, adulto
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- RHMGSU0292
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .